Sharps Technology (STSS) Q3 2025 earnings summary

Executive summary

• Transitioned from manufacturing to a medical device sales and distribution model, ceasing R&D and manufacturing after a settlement and spinoff of the Hungarian subsidiary.

• Adopted a digital asset treasury strategy in August 2025, focusing on accumulating Solana (SOL), with over 2.0 million SOL and $404M in digital assets by quarter-end.

• Raised $411M in August 2025 through private placements/PIPE financing, with proceeds in cash, SOL, and USDC, significantly improving liquidity.

• Reported a net loss of $105.3M for Q3 2025, primarily due to $101.3M in non-cash stock compensation and $7.5M in asset impairments.

• Holds over $267M in cash/stablecoins and $144M in SOL from PIPE financing.

Financial highlights

• Q3 2025 product revenue: $83,622; staking revenue: $2.2M; gross margin: $(1.17)M.

• Nine months ended September 30, 2025: product revenue $306K, staking revenue $2.2M, gross margin $(2.2)M.

• Generated $17.7M in combined staking revenue and digital asset fair-value gains in Q3 2025.

• Cash and stablecoin liquidity at $25.2M as of September 30, 2025.

• Warrantholders exercised 315,805 Series A warrants for $1.9M in net proceeds.

Outlook and guidance

• Liquidity deemed sufficient for at least 12 months due to digital asset holdings and recent financings.

• Focus on expanding distribution of medical devices, optimizing Solana ecosystem yields, and leveraging capital markets for growth.

• Share repurchase program of up to $100M approved in October 2025.